JP2022529370A5 - - Google Patents
Info
- Publication number
- JP2022529370A5 JP2022529370A5 JP2021562810A JP2021562810A JP2022529370A5 JP 2022529370 A5 JP2022529370 A5 JP 2022529370A5 JP 2021562810 A JP2021562810 A JP 2021562810A JP 2021562810 A JP2021562810 A JP 2021562810A JP 2022529370 A5 JP2022529370 A5 JP 2022529370A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- item
- group
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837829P | 2019-04-24 | 2019-04-24 | |
| US62/837,829 | 2019-04-24 | ||
| PCT/US2020/029465 WO2020219639A1 (en) | 2019-04-24 | 2020-04-23 | Ester and carbonate pyrimidine compounds as jak kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529370A JP2022529370A (ja) | 2022-06-21 |
| JP2022529370A5 true JP2022529370A5 (enExample) | 2023-04-04 |
| JP7470713B2 JP7470713B2 (ja) | 2024-04-18 |
Family
ID=70740750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562810A Active JP7470713B2 (ja) | 2019-04-24 | 2020-04-23 | Ｊａｋキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11155549B2 (enExample) |
| EP (1) | EP3958969B1 (enExample) |
| JP (1) | JP7470713B2 (enExample) |
| AR (1) | AR118768A1 (enExample) |
| CA (1) | CA3135383A1 (enExample) |
| ES (1) | ES2974577T3 (enExample) |
| HR (1) | HRP20240346T1 (enExample) |
| HU (1) | HUE066802T2 (enExample) |
| PL (1) | PL3958969T3 (enExample) |
| TW (1) | TW202106682A (enExample) |
| WO (1) | WO2020219639A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA49956B1 (fr) | 2017-10-27 | 2022-11-30 | Theravance Biopharma R&D Ip Llc | Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak |
| JP7470713B2 (ja) * | 2019-04-24 | 2024-04-18 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物 |
| JP7482152B2 (ja) * | 2019-04-24 | 2024-05-13 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | 皮膚疾患の処置のためのピリミジンｊａｋ阻害剤 発明の背景 |
| US20210212962A1 (en) * | 2020-01-13 | 2021-07-15 | Sol-Gel Technologies Ltd. | Methods and compositions for the treatment of granuloma annulare or subcutaneous inflammation and non-infection granulomatous diseases |
| AU2022263067A1 (en) * | 2021-04-22 | 2023-11-02 | Shenzhen Chipscreen Biosciences Co., Ltd. | Pharmaceutical composition containing jak3/jak1/tbk1 selective inhibitor and medical use thereof |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4919934A (en) | 1989-03-02 | 1990-04-24 | Richardson-Vicks Inc. | Cosmetic sticks |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| AU2001290912A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| BR0116493A (pt) | 2000-12-21 | 2003-09-30 | Vertex Pharma | Compostos de pirazol úteis como inibidores de proteìna cinase |
| ATE508126T1 (de) | 2005-11-16 | 2011-05-15 | Vertex Pharma | Als kinaseinhibitoren geeignete aminopyrimidine |
| TW200817391A (en) | 2006-06-30 | 2008-04-16 | Astrazeneca Ab | Novel compounds |
| AU2007269540B2 (en) | 2006-07-05 | 2013-06-27 | Exelixis, Inc. | Methods of using IGF1R and Abl kinase modulators |
| RU2014129740A (ru) | 2011-12-22 | 2016-02-10 | Ф.Хоффманн-Ля Рош Аг | Производные 2,4-диаминопиримидина в качестве ингибиторов серин/треонин киназы |
| WO2015094803A1 (en) | 2013-12-16 | 2015-06-25 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| NO2721710T3 (enExample) * | 2014-08-21 | 2018-03-31 | ||
| ES2924698T3 (es) | 2015-05-28 | 2022-10-10 | Theravance Biopharma R&D Ip Llc | Proceso e intermedios para la preparación de compuestos de naftiridina como inhibidores de quinasa JAK |
| WO2017189822A1 (en) | 2016-04-28 | 2017-11-02 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compounds as jak kinase inhibitors |
| MA49956B1 (fr) | 2017-10-27 | 2022-11-30 | Theravance Biopharma R&D Ip Llc | Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak |
| TWI740288B (zh) | 2018-11-27 | 2021-09-21 | 大陸商江蘇豪森藥業集團有限公司 | 含氮雜芳類衍生物調節劑、其製備方法和應用 |
| CN115925705B (zh) | 2018-11-30 | 2024-12-31 | 江苏豪森药业集团有限公司 | 杂芳类衍生物调节剂、其制备方法和应用 |
| JP7482152B2 (ja) | 2019-04-24 | 2024-05-13 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | 皮膚疾患の処置のためのピリミジンｊａｋ阻害剤 発明の背景 |
| JP7470713B2 (ja) | 2019-04-24 | 2024-04-18 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物 |
| CN113372364B (zh) | 2020-03-10 | 2024-05-31 | 明慧医药（上海）有限公司 | 一类jak激酶抑制剂及其制备和应用 |
| CN113372351A (zh) | 2020-03-10 | 2021-09-10 | 明慧医药（杭州）有限公司 | 一类jak激酶抑制剂及其制备和应用 |
-
2020
- 2020-04-23 JP JP2021562810A patent/JP7470713B2/ja active Active
- 2020-04-23 PL PL20726591.9T patent/PL3958969T3/pl unknown
- 2020-04-23 TW TW109113575A patent/TW202106682A/zh unknown
- 2020-04-23 ES ES20726591T patent/ES2974577T3/es active Active
- 2020-04-23 AR ARP200101152A patent/AR118768A1/es unknown
- 2020-04-23 HR HRP20240346TT patent/HRP20240346T1/hr unknown
- 2020-04-23 EP EP20726591.9A patent/EP3958969B1/en active Active
- 2020-04-23 CA CA3135383A patent/CA3135383A1/en active Pending
- 2020-04-23 WO PCT/US2020/029465 patent/WO2020219639A1/en not_active Ceased
- 2020-04-23 HU HUE20726591A patent/HUE066802T2/hu unknown
- 2020-04-23 US US16/856,280 patent/US11155549B2/en active Active
-
2021
- 2021-09-27 US US17/448,922 patent/US11845747B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022529371A5 (enExample) | ||
| US11357760B2 (en) | Method of treating liver fibrosis | |
| AU2020305979B2 (en) | Method for treating idiopathic pulmonary fibrosis | |
| CN102497864B (zh) | 用于预防或治疗由化疗诱发的疼痛的σ配体 | |
| JP2009536659A (ja) | 血液疾患の治療法 | |
| RU2011121567A (ru) | Изоиндолиновые соединения для применения при лечении рака | |
| ES2437346T3 (es) | Procedimiento para la producción de derivado de diamina | |
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| JP2022533182A5 (enExample) | ||
| JP2022031806A (ja) | アルテスナート含有組成物 | |
| RU2017131354A (ru) | Замещенные амино шестичленные насыщенные гетероалициклы в качестве ингибиторов dpp-iv длительного действия | |
| KR20160005356A (ko) | 방사선완화 약제학적 제형 | |
| WO2021000785A1 (zh) | 作为詹纳斯激酶1选择抑制剂的吡咯并[2,3-b]吡啶衍生物 | |
| JP5882296B2 (ja) | 創傷の予防及び治療のための組成物及び方法 | |
| CN1260784A (zh) | 作为pdeiv和tnf抑制剂的喹啉衍生物 | |
| RU2018130097A (ru) | Лечение экземы кистей | |
| WO2024050434A1 (en) | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES | |
| EP4367107A1 (en) | Novel compounds as inhibitors of pcsk9 | |
| EP2716639A1 (en) | Inhibitors of viral replication, their process of preparation and their therapeutical uses | |
| JP2006502168A5 (enExample) | ||
| US9796722B1 (en) | Hepatitis B viral assembly effectors | |
| JP2016525546A (ja) | トリグリセリド、総コレステロール、及び低密度リポタンパク質の血中濃度を低減する方法 | |
| JPWO2020004404A1 (ja) | ＩＬ−１β阻害薬 | |
| JP2021528479A5 (enExample) | ||
| JP2025529076A (ja) | ＡｈＲ媒介疾患の治療に使用するタピナロおよびそのアナログ製剤 |